

3. Varenhorst C, Hasvold P, Johansson S. Culprit and nonculprit recurrent ischemic events in patients with myocardial infarction: Data from SWEDEHEART. *J Am Heart Assoc* 2018;7:e007174. DOI: 10.1161/JAHA.117.007174.
4. Nakatani D, Sakata Y, Suna S. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. *Circ J* 2013; 77: 439–446.
5. Bhatt DL, Fox KA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med* 2006; 354: 1706–1717.
6. Bhatt DL, Flather MD, Hacke W. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol* 2007;49:1982-8.
7. Roe MT, Armstrong PW, Fox KA. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med* 2012; 367: 1297–1309.
8. Bonaca MP, Bhatt DL, Cohen M. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015; 372: 1791–1800.
9. Bonaca MP, Bhatt DL, Steg PG. Ischaemic risk a efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. *Eur Heart J* 2016; 37: 1133–1142.
10. Dellborg M, Bonaca MP, Storey RF. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. *Eur Heart J* 2017; 38(suppl): 794–795.
11. Magnani G, Storey RF, Steg PG. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. *Eur Heart J* 2016; 37: 400–408.
12. Bonaca MP, Bhatt DL, Storey RF. Ticagrelor in prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. *J Am Coll Cardiol* 2016; 67: 719–728.
13. Valgimigli M, Bueno H, Byrne RA. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur Heart J* 2018; 39: 213–254.
14. Neumann FJ, Sousa-Uva M, Ahlsson A. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eurointervention* 2019; 14: 1435–1534.
15. Hurlen M, Abdelnoor M, Smith P. Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* 2002; 347: 969–974.
16. Rothberg MB, Celestin C, Fiore LD. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. *Ann Intern Med* 2005; 143: 241–250.
17. Oldgren J, Budaj A, Granger CB. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *Eur Heart J* 2011; 32: 2781–2789.
18. Alexander JH, Lopes RD, James S. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med* 2011; 365: 699–708.
19. Mega JL, Braunwald E, Wiviott SD. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med* 2012; 366: 9–19.
20. Connolly SJ, Eikelboom JW, Bosch J. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 2018; 391: 205–218.
21. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2019; doi:10.1093.eurheartj.ehz425.

Nenechte si ujít **aktuální informace** o možnostech vzdělávání lékařů, lékárníků a dalších odborníků ve zdravotnictví

SOLEN
MEDICAL EDUCATION

SLEDUJTE NÁS NA SOCIÁLNÍCH SÍTÍCH



<https://www.facebook.com/SolenMedicalEducation/>
@SolenMedicalEducation



<https://twitter.com/MedicalSolen>
@MedicalSolen

